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In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none. In 2003–2004,
investigators in the Development of Antiretroviral Therapy in Africa (DART) Trial randomized persons initiating ART
in Uganda and Zimbabwe to either laboratory and clinical monitoring (LCM) or clinically driven monitoring (CDM).
CD4 cell counts were measured every 12 weeks in both groups but were only returned to treating clinicians for man-
agement in the LCM group. Follow-up continued through 2008. In observational analyses, dynamic marginal struc-
tural models on pooled randomized groups were used to estimate survival under different monitoring-frequency and
clinical/immunological switching strategies. Assumptions included no direct effect of randomized group onmortality
or confounders and no unmeasured confounders which influenced treatment switch and mortality or treatment
switch and time-dependent covariates. After 48 weeks of first-line ART, 2,946 individuals contributed 11,351 person-
years of follow-up, 625 switches, and 179 deaths. The estimated survival probability after a further 240 weeks
for post-48-week switch at the first CD4 cell count less than 100 cells/mm3 or non-Candida World Health Organi-
zation stage 4 event (with CD4 count <250) was 0.96 (95% confidence interval (CI): 0.94, 0.97) with 12-weekly
CD4 testing, 0.96 (95% CI: 0.95, 0.97) with 24-weekly CD4 testing, 0.95 (95% CI: 0.93, 0.96) with a single CD4
test at 48 weeks (baseline), and 0.92 (95% CI: 0.91, 0.94) with no CD4 testing. Comparing randomized groups by
48-week CD4 count, the mortality risk associated with CDM versus LCMwas greater in persons with CD4 counts of
<100 (hazard ratio = 2.4, 95% CI: 1.3, 4.3) than in those with CD4 counts of ≥100 (hazard ratio = 1.1, 95% CI: 0.8,
1.7; interaction P = 0.04). These findings support a benefit from identifying patients immunologically failing first-line
ART at 48 weeks.
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In high-income settings, human immunodeﬁciency virus
(HIV)-positive patients on antiretroviral therapy (ART) re-
ceive individualized care. Treating clinicians use routine
plasma HIV viral-load measurements and CD4 cell counts
every 3–6 months to monitor the efﬁcacy of personalized ini-
tial regimens and to trigger ART changes. In Africa, most
HIV patients receive ART through the public sector, on the
basis of standardized ﬁrst-line treatment regimens, with little
laboratory monitoring to identify failure and trigger switches
to second-line ART (1). In the Development of Antiretroviral
Therapy in Africa (DART) Trial, investigators randomized
3,316 Ugandan and Zimbabwean adults to receipt of either
laboratory and clinical monitoring (LCM), including 12-
weekly CD4 cell counts, or clinically driven monitoring
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(CDM), where CD4 counts were measured but results were
not returned to treating clinicians (2). Comparing randomized
groups over a median of 4.9 years of follow-up, there was a
small but signiﬁcant survival difference at 5 years (90% for
the LCM group vs. 87% for the CDM group), but at current
costs, 12-weekly CD4 monitoring was not cost-effective in
Uganda/Zimbabwe (3). Testing CD4 cell count less fre-
quently than every 12 weeks would reduce costs, but this
was not evaluated in a randomized comparison. The DART
data are ideal for observational analyses of different CD4
cell-count monitoring frequencies because all participants
had CD4 counts performed but switching was variable fol-
lowing low CD4 counts—ﬁrstly by design, since clinicians
did not receive test results in the CDM group and the LCM
CD4 switch threshold changed during the trial, and secondly
because, although compliance was high, it was not complete.
We therefore combined DART randomized groups and es-
timated survival under different monitoring-frequency and
switching strategies after 48 weeks on ART.We ﬁrst used dy-
namic marginal structural models and inverse weighting (4–
6) to compare survival under switching at the ﬁrst CD4 cell
count below a threshold of 10–100 cells/mm3 or the ﬁrst non-
esophageal Candida World Health Organization (WHO)
stage 4 event (7) (provided that CD4 count was <250 cells/
mm3 (8)) versus switching for the ﬁrst WHO 4 event alone.
Dynamic marginal structural models have previously been
used to estimate “when to start”ART (9). A “when to switch”
application is similar (6). Loosely, survival is estimated for
each switching strategy, censoring individuals if they become
“noncompliant” with the strategy, using weights to account
for censoring. We further estimated survival for CD4-count
monitoring frequencies ranging from every 12 weeks (12-
weekly) to a single CD4 measurement. The same methodology
can be utilized, provided that the CD4 test itself (as opposed
to the result) has no biological effect on survival (10). An in-
dividual’s “compliance” with a strategy (e.g., switch at ﬁrst
CD4 count <100 where CD4 counts are measured at baseline
and 48-weekly) then depends on the CD4 counts which
would have been observed under the strategy (at 0, 48, 96,
144, . . . weeks).
METHODS
At DARTenrollment in 2003–2004, ART-naive Ugandan/
Zimbabwean adults initiated triple-drug ART (zidovudine/
lamivudine plus abacavir, tenofovir, or nevirapine) (2). Par-
ticipants visited the study clinic every 4 weeks (>98% atten-
dance), when nurses administered standard symptom and
adherence checklists and prescriptions were dispensed. Par-
ticipants saw a physician and underwent lymphocyte subset
and hematology/biochemistry testing at weeks 4 and 12 and
then 12-weekly. All LCM results were returned to clinicians,
whereas CDM hematology/biochemistry results were returned
only if requested for clinical reasons or if therewas grade 4 tox-
icity; CDM lymphocyte subsets were never returned. Nurses
could refer participants to a physician at any time.
Following WHO guidelines (11), a switch to second-line
ART (with a ritonavir-boosted protease inhibitor) was dis-
couraged before 48 weeks. The switch decision was based
on clinical failure criteria (a WHO 4 event, or a WHO 3
event at the physician’s discretion, particularly if recurrent/
persistent) in both groups and immunological criteria (CD4
cell count <50 cells/mm3 or a conﬁrmed CD4 count <100
cells/mm3 from July 2006 onward) in the LCM group (not
the CDM group). LCM participants with a low CD4 count
could have a repeat CD4 count at/before their next nurse
visit. Within-class antiretroviral drug substitutions for ad-
verse events/drug-drug interactions were not considered treat-
ment switches.
Statistical methods
Study entry was the ﬁrst 4-week visit at/after 48 consecu-
tive weeks on ﬁrst-line ART (allowing interruptions of <31
days, usually because of inability to visit the clinic). Follow-
up ended at death, December 31, 2008 (trial closure), or the
last clinic visit for persons lost to follow-up. Individuals were
only classiﬁed as lost if, after clinic nonattendance, active
tracing through 3 home visits failed. Follow-up data were or-
ganized into 4-weekly intervals, beginning 0, 28, 56, . . .
days after baseline, corresponding to the nurse visit schedule.
Dynamic marginal structural models were used to estimate
survival under different hypothetical CD4 monitoring-
frequency and switching strategies (5, 10). Switching strate-
gies were deﬁned by current CD4 count dropping below a
certain threshold and/or occurrence of a WHO 4 event (or a
second WHO 3 event for some strategies). Because other
DART analyses showed that a CD4 “tie-breaker” at a <250-
cells/mm3 threshold would reduce unnecessary second-line
switches with viral load less than 400 copies/mL (8), WHO
3/4 events were used to deﬁne switching strategies only if the
last prior CD4 cell count was less than 250. To compare strat-
egies X = 1, 2, . . ., n, we created n copies of each individu-
al’s data. A participant was ﬁrst eligible for a second-line
switch under strategy X in the ﬁrst 4-week interval after his
or her CD4 cell count dropped below the strategy threshold
or within the same interval as the WHO event occurred, pro-
vided that the event occurred strictly before the switch. A
grace period of three 4-week intervals was permitted for
switching: the ﬁrst interval in which the participant was eli-
gible to switch and the following two 4-week intervals—a
period covering 1 scheduled physician visit. In practice,
this meant that participants were allowed 12–16 weeks to
switch regimens following a low CD4 cell count but 8–12
weeks to switch following WHO events, depending on when
the event occurred in the ﬁrst interval. For each strategy X,
participants were “artiﬁcially” censored when their data be-
came incompatible with X, either from switching before be-
coming eligible or from not switching by the end of the grace
period after becoming eligible. To adjust for potential bias
due to artiﬁcial censoring, we applied patient-time–speciﬁc
weights equivalent to the inverse of the estimated probability
of remaining uncensored (following strategy X) conditional
on covariate history.
We additionally censored a subgroup of participants ran-
domized to 12-week cycles of structured treatment interrup-
tions (STIs) 52 or 76 weeks after ART initiation in a DART
substudy (12). Participants randomized to receive continuous
therapy in the same substudy were upweighted, with weights
dependent on study center and LCM/CDM status; weights
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were approximately 2, so that persons randomized to receive
continuous therapy represented participants on STIs after
censoring in addition to themselves, assuming comparability
at randomization. To adjust for potential selection bias from
loss to follow-up, lost-to-follow-up weights were also esti-
mated using the factors included in the switching weights
and any previous switch to second-line ART (13). The time-
dependent product of switching, substudy, and lost-to-follow-
up weights was used toweight outcomemodels. Weights were
truncated at 10 (9).
Unless otherwise stated, we pooled participants from both
randomized groups (LCM/CDM) under the assumptions that
1) participants were comparable at baseline (48 weeks on
ﬁrst-line ART); 2) there was no direct effect of randomized
group on mortality or any confounders—that is, any effect
on mortality or time-dependent covariates (e.g., CD4 count,
WHO 4 events) of access to CD4 test results in the LCM
group or lack of access to results in the CDM group was in-
direct and occured through switching; and 3) there were no
unmeasured confounders which inﬂuenced treatment switch
and mortality or treatment switch and time-dependent co-
variates (Figure 1). The DART Trial found no difference
between randomized groups in any toxicity outcome (2), sug-
gesting a lack of impact of other (non-CD4) laboratory tests.
Switching and outcome models were ﬁtted without including
randomized group. The rationale for pooling groups and re-
lated assumptions are discussed further in Web Appendix 1
(which includes Web Figure 1 andWeb Table 1), available at
http://aje.oxfordjournals.org/.
The probability of switching to second-line ART during in-
terval k, A(k), where A(k) = 1 indicates a switch before the end
of interval k, was estimated using pooled logistic regression:
logit(P½AðkÞ ¼ 1jAðk  1) ¼ 0, DðkÞ ¼ 0, V ; LðkÞÞ
¼ α0ðkÞ þ α02V þ α02LðkÞ;
where α0(k) is an interval-speciﬁc intercept (modeled by re-
stricted cubic splines with knots at the 10th, 50th, and 90th per-
centiles), Aðk  1) ¼ 0 indicates being on ﬁrst-line ART up to
and including interval k− 1,D(k) = 0 if an individual survived
to the end of interval k, V includes baseline factors at ART ini-
tiation and 48 consecutive weeks on ﬁrst-line ART (analysis
baseline), and LðkÞ is history of time-dependent confounders
up to interval k. Risk factors for mortality and likely confound-
ers were included in the switch model (14). Baseline factors
included all possible combinations of study center and ﬁrst-
line ART regimen and the following factors at 48 weeks: CD4
cell count (<100, 100–199, or ≥200 cells/mm3), body mass
index (weight (kg)/height (m)2; ≤18.5, >18.5), hemoglobin
concentration (<8 g/dL, ≥8 g/dL), and WHO 4 event 24–48
weeks after starting ART. Time-dependent variables included
in LðkÞ were current CD4 cell count (restricted cubic spline
with knots at counts of 15, 50, 100, and 200 cells/mm3), body
mass index (≤18.5, >18.5), and hemoglobin concentration
(<8 g/dL, ≥8 g/dL) (for all, the most recent value prior to in-
terval k or on the ﬁrst day of interval k), use of cotrimoxazole
in the previous interval if this was during the ﬁrst 72 weeks
on ART (15), ≥3 of the previously scheduled 6 nurse visits
missed, patient-reported missed ART doses during the 4
weeks prior to interval k, and history of WHO stage 3/4 events
occurring with CD4 count <250. Body mass index and hemo-
globin were categorized because associations were nonlinear.
Only the most important predictor (current CD4 count) was
modeled using a cubic spline to reduce positivity problems.
History of nontuberculosis WHO 3/4 events was included as
a 5-category variable with the highest level dominant, as
follows: no history in intervals k − 5, . . ., k; WHO 3 event
or esophageal Candida in k − 5, . . ., k − 3; WHO 3 event/
esophageal Candida in k − 2, . . ., k; non-Candida WHO 4
event in k − 5, . . ., k− 3; or non-Candida WHO 4 event in
k− 2, . . ., k. WHO stage 3/4 events in the current interval k
were included provided that they strictly preceded the switch,
since some participants returned to the clinic between visits
when sick and had their regimens switched; excluding events
occurring in interval k was thus likely to introduce unmea-
sured confounding. An interaction between non-Candida
WHO4 events in interval k− 2, . . ., k and current CD4 count
(<100, ≥100) was included. We considered esophageal Can-
dida separately from other WHO 4 events because it is non-
fatal and is widely recognized as less severe (16). History of
tuberculosis was considered separately from other WHO 3/4
events since clinicians often delayed a switch to start tuber-
culosis treatment because of potential drug-drug interactions;
a 5-level variable ordered similarly to the one above was in-
cluded (pulmonary tuberculosis =WHO 3, extrapulmonary =
WHO 4). Completeness of 4-weekly nurse visits (98%) and
12-weekly physician visits (99%) was very high. Missing val-
ues were imputed by car the most recent observation forward
R C0 E0 D1 C1 E1 D2
U
Figure 1. Directed acyclic graph illustrating associations between
randomized trial group (R), time-dependent covariates at time t (Ct,
e.g., CD4 cell count), switch to second-line antiretroviral therapy
(ART) before/at time t (Et), death before/at time t (Dt), and unmeasured
common causes of C and D (U ) among human immunodeficiency
virus–positive patients on ART. Arrows represent direct causal rela-
tionships between variables. Time-dependent covariates (C) at a given
time point influence whether treatment is switched to second-line
ART at that time point or subsequently (E ) and influence time-
dependent covariates (C) at later time points andmortality (D). Switch-
ing treatment regimens (E ) influences time-dependent covariates (C),
switching (E ), and mortality at later time points (D). The following as-
sumptions are made: R has no effect on C other than via E; R has no
effect on D other than via E; there are no unmeasured common
causes of E and C or E and D; and R is randomized. Different line
styles and colors are used only to distinguish the effects of randomized
group, different covariates, exposures, and death: Effects of R are
shown by solid black lines; effects of C0 by dashed gray lines; effects
of E0 by dashed black lines; effects of D1 by solid gray lines; effects of
C1 by dotted black lines; effects ofE1 by dashed-dotted gray lines; and
effects of U by dotted gray lines.
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(current CD4 count >12/24weeks previously for 2%/0.4% of intervals, respectively; other variables were similar). Sensitivity analy-
ses additionally included alternative WHO 3/4 event histories, ﬁner CD4 categories for interactions with event history, and CD4
count and body mass index prior to the current one (results were similar; not shown).
To estimate survival under different CD4 monitoring frequencies, we followed Robins et al. (10) and deﬁned each CD4 count
as observed or unobserved, depending on the monitoring frequency (e.g., under 48-weekly monitoring, CD4 counts would be
observed at 0, 48, 96, . . . weeks and unobserved at 12, 24, 36, 60, 72, 84, . . . weeks). We then deﬁned compatibility with
switching strategies from observed CD4 counts only (i.e., to deﬁne “compliance” with the switching strategy, we ignored “un-
observed” CD4 counts). For example, under 48-weekly CD4 monitoring, CD4 thresholds could only be crossed at 0, 48, 96, . . .
weeks and participants who switched in response to other CD4 counts were censored at the time of the switch. Inverse-probability
weights were from a switching model including all CD4 counts as was done previously, because to control confounding, weights
must depend on the original data, including all measured CD4 counts (10).
We estimated survival under an approximately uniform distribution of switching times across the grace period (5). Nonstabi-
lized weights (Wx(k) for strategy X) were estimated by
WxðkÞ ¼ I½CxðkÞ ¼ 0Qk
j¼1 f pAð jÞI½ j<Qxg
Ym
r¼0
1 1/(mþ 1 rÞ
pAðQx þ rÞ
 I½kQxþr; AðQxþrÞ¼0(
×
1/(mþ 1 rÞ
1 pAðQx þ rÞ
 I½kQxþr; AðQxþr1Þ¼0; AðQxþrÞ¼1)
;
where I [·] equals 1 if · is true and 0 otherwise, pAðkÞ equals
1 ðP½AðkÞ ¼ 1jAðk  1) ¼ 0, DðkÞ ¼ 0, V ; LðkÞÞ; CX(k)
is an artiﬁcial censoring indicator such that CX(k) = 0 if an in-
dividual remains uncensored to the end of interval k under
strategy X, Qx is the ﬁrst interval in which an individual is el-
igible to switch under strategy X,m is the number of intervals
in the grace period excluding the ﬁrst one (here, m = 2), and r
indexes the 4-week interval within the grace period (here, in-
terval 0, 1, 2). The denominator of the ﬁrst component is the
probability of not switching before becoming eligible to
switch. The denominator of the second component is based
on the probability of the observed treatment within the grace
period, and the numerator forms the uniform distribution of
treatment switches across the grace period.
The effects of switching strategies (indexed by X) on mor-
tality were estimated in the expanded data set using weighted
pooled logistic regression:
logit(P½Dðkþ1)¼ 1jDðkÞ¼ 0,CxðkÞ¼ 0,X;CFðkþ1)¼ 0])
¼ θ0ðkÞþθ01hðXÞþθ02gðXÞþθ03hðXÞkmþθ04gðXÞkm;
whereD(k) = 1 if an individual died during interval k,CF(k) =
0 if an individual remained uncensored by loss to follow-up/
STI to the end of interval k, and θ0ðkÞ is an interval-speciﬁc
intercept (restricted cubic spline). Either h(X) or g(X) is ﬁtted.
h(X) is a linear function of 10 CD4-based strategies, “switch
following ﬁrst CD4 count < x or ﬁrst non-CandidaWHO 4,”
with x ranging from 100 to 10 in 10-cell/mm3 drops (h(X) = 0
for event-only-based strategies). g(X) is a categorical variable
for 2 event-only-based strategies (g(X) = 0 for CD4-based
strategies) (Web Appendix 2). h(X)km and g(X)km are in-
teraction(s) between strategy(s) and follow-up time (where
km = 1 more than 96 weeks from baseline and 0 otherwise).
In sensitivity analyses, we considered a spline function for
h(X), and we reduced the number of strategies from 12 to 4
by considering only 2 options for x, CD4 <100 or CD4 <50,
and ﬁtting a categorical variable for h(X). Participants who had
not switched prior to interval kwere assumed to have the same
mortality risk in interval k irrespective of whether or not they
switched during k; that is, we modeled the probability of death
in interval k + 1 using weights computed to the end of interval
k. Monitoring-frequency strategies were modeled as categori-
cal variables keeping the CD4-based strategy ﬁxed, using the
outcome model
logit(P½Dðkþ1)¼ 1jDðkÞ¼ 0,CxðkÞ¼ 0,X;CFðkþ1)¼ 0])
¼ θ0ðkÞþθ01 f ðXÞþθ02 f ðXÞkm;
where f (X) is a categorical variable deﬁning CD4-count
monitoring frequency and f (X)km is an interaction between
CD4-count monitoring frequency and follow-up time. Ini-
tially, 6 monitoring strategies were considered: 12-, 24-, 48-,
or 96-weekly CD4 cell-count monitoring (all with the ﬁrst
CD4 count at baseline), 1 CD4 count measured at baseline
only, and no CD4 monitoring. The beneﬁt of a single CD4
count at baseline or 24, 48, . . ., 240 weeks postbaseline versus
no CD4 monitoring (10 strategies) was estimated in a second
model of the same form. The models’ predicted values were
used to estimate survival, with 95% conﬁdence intervals com-
puted using a nonparametric bootstrap (500 replicates, not de-
pending on randomized group).
RESULTS
Of the 3,316 DART participants (2), we excluded 137
(4%) entered into a nonrandomized pilot STI study 28
weeks after ART initiation, as well as 8 (3 LCM, 5 CDM)
switched to second-line ART, 2 (2 LCM) randomized to
STIs, 178 (80 LCM, 98 CDM) who had died, and 45 (21
LCM, 24 CDM) who were lost to follow-up before 48 con-
secutive weeks on ﬁrst-line ART.
All 2,946 participants included had pre-ART CD4 cell
counts less than 200 cells/mm3 (median, 86 cells/mm3; Table 1).
After 48 consecutive weeks on ﬁrst-line ART, participants
in the LCM (n = 1,474) and CDM (n = 1,472) groups were
similar, with median CD4 cell counts of 201 cells/mm3 and
200 cells/mm3 respectively; 320 of the 2,946 participants (11%)
still had CD4 counts less than 100 cells/mm3. Excluding and
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upweighting follow-up after randomization to STI and con-
tinuous therapy, respectively (see Methods), produced 11,351
person-years (1,089 person-years (10%) on second-line ART),
including 179 deaths (69 deaths (39%) on second-line ART).
A total of 190 participants (6%) were lost to follow-up.
Predictors of a switch to second-line treatment included
CD4 count and history of WHO events; 73% of those switch-
ing regimens had current CD4 counts under 100 (43% had
CD4 counts <50), and 62% switching with CD4 counts of
≥100 had had a WHO 3/4 event in the previous 12 weeks.
Characteristics at treatment switch differed in the LCM and
CDM groups, broadly following the protocol (Table 2).
Ninety-one percent of those switching with a CD4 count
<100 and no recent WHO 3/4 event were LCM participants,
Table 1. Characteristics and Follow-up of Included Participants Who Completed 48 Consecutive Weeks on First-Line Antiretroviral Therapy,
DART Trial, Uganda and Zimbabwe, 2003–2008
Characteristic
LCM Group (n = 1,474) CDM Group (n = 1,472) All Participants (n = 2,946)
No. % Median (IQR) No. % Median (IQR) No. % Median (IQR)
ART Initiation (DART Randomization)
Age, years 37 (32–42) 37 (32–42) 37 (32–42)
Sex
Male 506 34 528 36 1,034 35
Female 968 66 944 64 1,912 65
World Health Organization disease stage
2 332 23 292 20 624 21
3 824 56 836 57 1,660 56
4 318 22 344 23 662 22
CD4 cell count, no. of cells/mm3 84 (33–138) 86 (31–140) 86 (32–139)
Initial ART regimen
Combivir + tenofovir 1,072 73 1,081 73 2,153 73
Combivir + abacavir 259 18 250 17 509 17
Combivir + nevirapine 143 10 141 10 284 10
Baselinea
Time since ART initiation, weeks
48 1,442 98 1,450 99 2,892 98
>48–≤72b 17 1 9 1 26 1
>72b 15 1 13 1 28 1
CD4 cell count, no. of cells/mm3 201 (140–282) 200 (140–281) 201 (140–281)
<50 40 3 44 3 84 3
50–99 117 8 119 8 236 8
100–199 569 39 565 38 1,134 38
≥200 748 51 744 51 1,492 51
Follow-up After 48 Consecutive Weeks on First-Line ARTc
Person-years of follow-up on first-line ART 5,045 5,216 10,262
No. of deaths on first-line ART 51 59 110
No. of participants who switched to second-line
ART
340 285 625
Person-years of follow-up on second-line ART 665 424 1,089
No. of deaths on second-line ART 24 45 69
Abbreviations: ART, antiretroviral therapy; CDM, clinically driven monitoring; DART, Development of Antiretroviral Therapy in Africa; IQR,
interquartile range; LCM, laboratory and clinical monitoring.
a At 48 consecutive weeks on first-line ART.
b Most commonly due to interruptions for adverse events.
c Participants who had structured treatment interruptions in a randomized substudy (n = 405) were censored at the first structured treatment
interruption, and those randomized to continuous therapy in the substudy were upweighted (by approximately 2; see Methods). Person-years,
deaths, and switches shown here include this upweighting. Numbers of deaths upweighted: for persons on first-line ART, 5 in LCM group and
2 in CDM group; for persons on second-line ART, 1 in LCM group and 2 in CDM group. Numbers of switches upweighted: 12 in LCM group, 15 in
CDM group.
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whereas 76% of those switching following a recent non-
Candida WHO 4 event were CDM participants. Although
similar numbers of persons in the LCM (448/1,474; 30%)
andCDM (468/1,472; 32%) groups became eligible to switch
for having a CD4 count less than 100 cells/mm3 or a non-
Candida WHO 4 event (with CD4 <250) (Table 3), 72 out
of 448 (16%) LCMparticipants switched during the grace pe-
riod as compared with 20 of 468 (4%) CDM participants.
Few LCM participants became eligible to switch under a
strategy delaying the switch to the ﬁrst WHO 4 event (63/
1,474; 4%) or this or 2 WHO 3 events/esophageal Candida
(110/1,474; 7%), because LCM participants failing ﬁrst-line
ART switched earlier following low CD4 counts.
Comparing groups as randomized, estimated survival from
baseline (48 consecutive weeks on ﬁrst-line ART) was 95%
192 weeks (3.7 years) later and 94% 240 weeks (4.6 years)
later in LCM participants versus 93% and 92%, respectively,
in CDM participants (hazard ratio = 1.40, 95% conﬁdence in-
terval (CI): 1.02, 1.92; P = 0.04). CD4 <50/WHO 4 events
were the recommended switching criteria in the LCM group
up to July 2006, and CD4 <100/WHO 4 events were the rec-
ommended criteria from July 2006 onward (following WHO
(11)); pooling randomized groups, the estimated survival for
this strategy was marginally higher than that observed in the
LCM group, consistent with small improvements under full
protocol compliance. Similarly, the estimated survival for
switching at the ﬁrst WHO 4 event, or the ﬁrst WHO 4
event/multiple WHO 3 events, was similar to observed sur-
vival in the CDM group (Table 3). Under 12-weekly CD4
testing, survival was highest for those switching at CD4 <100
or the ﬁrst non-Candida WHO 4 event (with CD4 <250).
Using a linear term for the effect of CD4-based strategies, es-
timated survival 240 weeks after baseline was 96% (95% CI:
94, 97), 95% (95%CI: 94, 96), and 92% (95%CI: 91, 94) for
switching at CD4 <100, CD4 <50, and no CD4 threshold,
respectively (each with a non-Candida WHO 4 event as
above) (Table 3). Beneﬁts from switching at CD4 <100/non-
Candida WHO 4 were 1.0% (95% CI: 0.0, 1.8) in compari-
son with CD4 <50/non-CandidaWHO 4 and 3.5% (95% CI:
1.4, 5.6) in comparison with non-Candida WHO 4 events
only. Results were similar when we ﬁtted only these 2 CD4-
based strategies as categories rather than ﬁtting 10 strategies
with a linear effect. Adding switching after 2 WHO 3/esopha-
geal Candida events produced little survival improvement in
comparison with switching for the ﬁrst WHO 4 event (0.6%,
95% CI: −0.7, 2.0).
Under a strategy deﬁned by switching at the ﬁrst CD4
count <100 or non-Candida WHO 4 event (CD4 <250), we
found no survival advantage at 240 weeks for 12-weekly
CD4 counts as compared with 24-weekly CD4 counts
Table 2. Characteristics of Participants at Switch in Antiretroviral Therapy (ART) Regimen After 48 Consecutive
Weeks on First-Line ART, DART Trial, Uganda and Zimbabwe, 2003–2008
CD4 Cell Count and Event Typea
LCM Group
(n = 340b)
CDM Group
(n = 285b)
All Participants
(n = 625b)
No. Row % No. Row % No. Column %
<50 cells/mm3
No event 98 85 17c 15 115 18
WHO 3 event or esophageal Candida 19 19 80 81 99 16
WHO 4 event 9 17 44 83 53 8
50–99 cells/mm3
No event 116 96 5c 4 121 19
WHO 3 event or esophageal Candida 23 48 25 52 48 8
WHO 4 event 7 37 12 63 19 3
100–249 cells/mm3
No event 38 76 12c 24 50 8
WHO 3 event or esophageal Candida 15 39 23 61 38 6
WHO 4 event 11 44 14 56 25 4
≥250 cells/mm3
No event 2 14 12c 86 14 2
WHO 3 event or esophageal Candida 1 5 20 95 21 3
WHO 4 event 1 5 21 95 22 4
Abbreviations: ART, antiretroviral therapy; CDM, clinically driven monitoring; DART, Development of Antiretroviral
Therapy in Africa; LCM, laboratory and clinical monitoring; WHO, World Health Organization.
a AWHO stage 3 or 4 event in the current 4-week interval or one of 2 previous 4-week intervals.
b Participantswho had structured treatment interruptions in a randomized substudy (n = 405)were censoredat the first
structured treatment interruption, and those randomized to continuous therapy in the substudy were upweighted
(by approximately 2; see Methods). Numbers of switches upweighted: 12 in LCM group, 15 in CDM group.
c CDM participants switched without WHO 3/4 events may have had clinical events which did not meet predefined
protocol criteria for WHO 3/4 events.
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Table 3. Compliance With Different Antiretroviral Treatment Switching and CD4 Cell-Count Monitoring Strategies and Estimated Survival, DART Trial, Uganda and Zimbabwe, 2003–2008
Switching or CD4 Cell-Count
Monitoring Strategy
LCM Group CDM Group All Participants
No. of
Persons
Switcheda
No.
Eligible to
Switcha
%b No. ofDeathsc
No. of
Persons
Switcheda
No.
Eligible to
Switcha
%b No. ofDeathsc
No. of
Persons
Switcheda
No.
Eligible to
Switcha
%b No. ofDeathsc
Survival
Probability
at 192
Weeksd
95% CI
Survival
Probability
at 240
Weeksd
95% CI
Switching Strategy Recommended in the LCM Group During the Trial (CD4 Counts Measured Every 12 Weeks)
CD4 count <50 cells/mm3
up to June 30, 2006, and
<100 cells/mm3
thereafter or
non-Candida WHO
4 event (CD4 count
<250)e
211 354 60 60 54 376 14 36 265 730 36 96 0.96 0.94, 0.97 0.95 0.94, 0.97
CD4 Counts Measured Every 12 Weeks, Switching Strategies Varied
CD4 count <100 cells/mm3
or non-Candida WHO
4 event (CD4 count <250)
72 448 16 47 20 468 4 28 92 916 10 75 0.97 0.95, 0.98 0.96 0.94, 0.97
CD4 count <50 cells/mm3 or
non-Candida WHO
4 event (CD4 count <250)
103 218 47 58 38 305 12 42 141 523 27 100 0.96 0.95, 0.97 0.95 0.94, 0.96
2 WHO 3 events or
esophageal Candida
(CD4 count <250) or
non-Candida WHO
4 event (CD4 count <250)
45 110 41 58 94 231 41 66 139 341 41 124 0.94 0.93, 0.95 0.93 0.91, 0.94
Non-Candida WHO 4 event
(CD4 count <250)
25 63 40 57 62 144 43 73 87 207 42 130 0.94 0.92, 0.95 0.92 0.91, 0.94
Switch at First CD4 Cell Count <100 Cells/mm3 or Non-Candida WHO Stage 4 Event (CD4 Count <250), CD4 Monitoring Frequency Varied
CD4 count measured at
baselinef and every
12 weeks thereafter
72 448 16 47 20 468 4 28 92 916 10 75 0.97 0.95, 0.98 0.96 0.94, 0.97
CD4 count measured at
baselinef and every
24 weeks thereafter
79 387 20 52 24 425 6 31 103 812 13 83 0.97 0.95, 0.98 0.96 0.95, 0.97
CD4 count measured at
baselinef and every
48 weeks thereafter
68 311 22 54 32 378 8 37 100 689 15 91 0.96 0.95, 0.97 0.95 0.93, 0.96
CD4 count measured at
baselinef and every
96 weeks thereafter
59 256 23 53 40 337 12 42 99 593 17 95 0.96 0.95, 0.97 0.95 0.93, 0.96
CD4 count measured at
baseline onlyf
31 199 16 51 39 260 15 47 70 459 15 98 0.96 0.95, 0.97 0.95 0.93, 0.96
Abbreviations: ART, antiretroviral therapy; CDM, clinically drivenmonitoring; CI, confidence interval; DART, Development of Antiretroviral Therapy in Africa; LCM, laboratory and clinical monitoring; WHO,
World Health Organization.
a Participants who had structured treatment interruptions in a randomized substudy (n = 405) were censored at the first structured treatment interruption, and those randomized to continuous therapy in
the substudy were upweighted (by approximately 2; see Methods).
b Percentage of participants eligible to switch who switched within the grace period.
c Total number of deaths in participants compatible with strategy at the time of death (with weighting for structured treatment interruptions as described in footnote “a” above).
d Survival from baseline (48 consecutive weeks on first-line ART).
e Recommended CD4-based switching in the LCM group was changed from <50 cells/mm3 to <100 cells/mm3 in July 2006.
f Baseline was defined as the first 4-week visit at or after 48 consecutive weeks on first-line ART.
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(−0.2%, 95% CI: −1.4, 0.7) and observed only small, non-
signiﬁcant survival advantages for 12-weekly CD4 counts
compared with less frequent CD4-monitoring strategies, in-
cluding a single (baseline) CD4 count 48 weeks after ART
initiation (0.9% (95% CI: −1.0, 2.7) at 240 weeks) (Table 3,
Figure 2). Compared with no CD4 monitoring, the survival
beneﬁt derived from a single CD4 count after 48 weeks of
ﬁrst-line ART was signiﬁcant (2.4% (95% CI: 1.3, 3.9) at
240 weeks). Under 12-weekly CD4 counts, 2.2% of follow-
up would be spent with CD4 count <100 as compared with
2.7% and 3.6% under 24-weekly and 48-weekly CD4 counts,
6.6% with a single CD4 count after 48 weeks of ﬁrst-line
ART, and 9.4% with no CD4 monitoring (Web Figure 2).
A single CD4 count after 48 weeks of ﬁrst-line ART im-
proved survival at 240 weeks by 1.2% (95% CI: 0.2, 2.3)
and 1.9% (95% CI: 0.7, 3.5) as compared with a single CD4
count after 72 and 96 weeks of ﬁrst-line ART, respectively.
In sensitivity analyses, we found similar survival differ-
ences across different CD4 testing frequencies when switching
criteria were varied to exclude a switch following extrapul-
monary tuberculosis, to include a switch at all non-Candida
WHO 4 events irrespective of current CD4 count, or to de-
pend on event history lagged by 4 weeks (Web Table 2), and
irrespective of the use of cotrimoxazole during weeks 48–72
of ART (WebAppendix 3 (includingWeb Table 3)). Notably,
in all sensitivity analyses, a single CD4 count after 48 weeks
of ﬁrst-line ART signiﬁcantly improved survival 240 weeks
later in comparison with no CD4monitoring: by 2.4% (95%CI:
1.3, 3.6) excluding extrapulmonary tuberculosis, by 2.3%
(95% CI: 1.3, 3.5) with no CD4 restriction, and by 1.8%
(95% CI: 0.9, 3.1) using lagged events. Using raw rather
than truncated weights, the beneﬁts of CD4 monitoring were
slightly higher. We also considered a combined outcome in-
cluding death or loss to follow-up; the percentages of persons
alive and under follow-up were 2.4% (95%CI:−0.7, 5.3) and
1.9% (95% CI: 0.3, 3.3) higher for 12-weekly CD4 counts
and a single 48-week CD4 count, respectively, in comparison
with no CD4 monitoring.
Given the substantial beneﬁts of a single CD4 count sug-
gested by the dynamicmarginal structural model, we compared
DART randomized groups by CD4 count at 48 consecutive
weeks of ﬁrst-line ART (Figure 3). Fifty-four (30%) of the
179 subsequent deaths occurred among the 11% of participants
with CD4 counts less than 100 cells/mm3 at 48 weeks—16 in
the LCM group versus 38 in the CDM group (hazard ratio =
2.39, 95%CI: 1.32, 4.32). In contrast, therewere 59 LCMdeaths
versus 66 CDM deaths among participants with CD4 cell
counts greater than or equal to 100 cells/mm3 at 48 weeks
(hazard ratio = 1.13, 95% CI: 0.77, 1.65; interaction P for
heterogeneity = 0.04). Excluding the 320 participants with
CD4 counts less than 100 at 48 weeks, only 525 of 2,626
(20%) participants had a CD4 count less than 100 without a
prior WHO 4 event during the subsequent 4 years of follow-
up; the observed beneﬁt of CD4 monitoring is small at the
population level because such persons are in the minority.
DISCUSSION
We applied dynamic marginal structural models to DART
Trial data to estimate survival under different switching strat-
egies among HIV-infected Ugandan/Zimbabwean adults
who completed 48 consecutive weeks of ﬁrst-line ART.
Using these observational analysis methods, we found that
with 12-weekly CD4 monitoring, switching therapy when
CD4 count drops below 100 cells/mm3 is associated with
a small but signiﬁcant survival advantage compared with
switching at clinical events.
Using observational analyses within a trial “cohort” fur-
ther enabled us to investigate the impact of decreasing the fre-
quency of CD4 monitoring on ART effectiveness. To our
knowledge, this is a novel application of these methods. In
DART, treating clinicians had not received CDMCD4 counts
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patients on antiretroviral therapy (ART) for different CD4 cell-count
monitoring strategies, all assuming a switch in treatment regimen (to
second-line ART) at the first observed CD4 count less than 100
cells/mm3 or the first non-Candida World Health Organization stage
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rica (DART) Trial, Uganda and Zimbabwe, 2003–2008. Baseline
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during the trial, although they were measured; this led to suf-
ﬁcient variability in switching to allow us to explore the impact
of different CD4 monitoring strategies. We found that 24-
weekly CD4 cell counts, used in practice in some African coun-
tries (17), were not inferior to 12-weeklyCD4 counts in terms of
mortality. Of note, a singleCD4 cell count taken 48 weeks after
ART initiation, switching regimens if the count was less than
100 cells/mm3, offered a signiﬁcant survival beneﬁt compared
with clinicalmonitoring only. Direct comparison of randomized
groups by 48-week CD4 count supported this, showing that the
beneﬁt derived from CD4 monitoring was signiﬁcantly greater
among personswith CD4 counts less than 100 at 48weeks, with
little difference between randomized groups in those with
higher CD4 counts. These results suggest that in places
where limited laboratory facilities are available, 1 CD4 cell
count taken approximately 1 year after ART initiation to iden-
tify lack of response to ﬁrst-line ART and trigger a switch in
treatment regimen could improve survival.
The question of how frequently routine ART laboratory
monitoring should occur has only been assessed in stochastic
modeling studies of cost-effectiveness. Only 1 study (18) di-
rectly compared 3-monthly monitoring with 6-monthly mon-
itoring, for both CD4 and CD4 + viral load, and found a
<1-month gain in life expectancy from 3-monthly monitoring
versus 6-monthly monitoring across a range of ART initia-
tion strategies. However, that study used a 50% CD4 decline
from peak level to deﬁne immunological failure, in contrast
to the more sensitive but relatively late CD4 <100 threshold
used in DART (19). The question of howmuch further survival
beneﬁts might increase if switching were done earlier at CD4
thresholds greater than or equal to 100 (or based on plasma
HIV RNA level) cannot be addressed using DART data, be-
cause these strategies were not followed by sufﬁcient num-
bers of participants. Although further beneﬁts from other
WHO immunological failure criteria (less than pre-ART or
50% decline from peak) may be possible, and although other
studies have suggested high survival at 5 years if a second-
line switch immediately follows WHO immunological fail-
ure (20), gains are likely to be small given that in this analysis
96% of those alive after 48 weeks on ART were predicted to
survive a further 4.6 years with 24-weekly CD4 monitoring
and a switch at <100 cells/mm3.
We pooled DART randomized groups in order to explore
the effects of different strategies, because within each ran-
domized group switching patterns were similar. This required
assuming no direct effect of group on mortality. There was
some suggestion of a nonsigniﬁcant residual beneﬁt for CDM
participants versus LCM participants (Web Appendix 1),
which could suggest that clinicians took better care of pa-
tients where they had no access to CD4 counts and that con-
founders were missed or unmeasured; if this were the case,
we may have underestimated the added beneﬁt of more fre-
quent routine CD4 monitoring, since estimates of survival
under strategies including less frequent/no CD4 monitoring
depended heavily on survival in the CDM group. However,
because participants were enrolled in a clinical trial, we had
systematic and close-to-complete data on use of other medi-
cations, visit attendance, ART adherence, and laboratory and
clinical measures, and multiple sensitivity analyses incorpo-
rating different aspects of these factors did not affect results.
Application of these methods to a realistic scenario more
complex than previously considered raised several important
methodological issues. Firstly, clinicians often requested a
second CD4 cell count rather than switch for a single low
CD4 count. Since conﬁrmatory CD4 counts were only avail-
able at selected times and in a subset of patients in our study,
they could not sensibly be incorporated into a strategy. Sec-
ondly, allowing different grace periods for different clinical
events would have been more appropriate clinically, because
clinicians often delay a switch to second-line ART following
a tuberculosis diagnosis (WHO 3/4 event) due to drug inter-
actions between rifampicin and boosted protease inhibitors.
This is complicated by the fact that patients may be eligible
to switch for more than 1 event within overlapping intervals;
so, for example, a patient whose CD4 count drops below 100
may become eligible to switch but then receive a tuberculosis
diagnosis within the grace period prior to switching. We con-
sidered strategies including and excluding WHO 4 extrapul-
monary tuberculosis as a trigger for switching to ensure that
our results regarding CD4 monitoring frequency were robust.
In summary, our results demonstrate how data from well-
conducted large randomized controlled trials can be exploited
using rigorous observational analyses to address clinical ques-
tions beyond those originally anticipated. Trial data have sev-
eral strengths, including typically higher completeness and
collection of data on additional items not available within clin-
ical cohorts or available less frequently in interval cohorts (21).
As with all observational analyses, we cannot exclude the pos-
sibility of bias, but our ﬁndings support increasing access to
CD4 cell counts for all patients on ART rather than increasing
the frequency of routine laboratory monitoring for patients in
easy-to-access areas.
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